Clinical trials for lung cancer

112 currently recruiting clinical trials
Lung cancer

Phase 3 Lung cancer
#NCT06012435
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic Immunotherapy Chemotherapy Targeted therapy
Systemic Treatment-Naive
CHU - Haut-Lévêque - Bordeaux (Pessac), Hôpital Bichat - Claude Bernard - AP-HP (Paris), Centre Hospitalier Universitaire de Toulouse (Toulouse), Centre Hospitalier Universitaire de Lille (Lille), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg) (and 10 more...)
Seagen
Phase 3 Lung cancer
#NCT05920356
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C Systemic Treatment-Naive PDL1 Negative (< 1%)
Targeted therapy Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Centre Hospitalier de Cornouaille (Quimper), Centre Antoine Lacassagne (Nice), Institut de Cancérologie et d’Hématologie Universitaire de Saint-Étienne (CHU Saint-Étienne) (Saint-Priest-en-Jarez), Centre Hospitalier Universitaire de Lille - Institut Cœur Poumon (Lille), Centre Hospitalier Universitaire de Nîmes (Nîmes) (and 24 more...)
Amgen
Phase 3 Lung cancer
#NCT05668988
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic EGFR Systemic Treatment-Naive
Centre Hospitalier Universitaire de Nantes (Nantes), Hôpital d'instruction des Armées Bégin (Saint-Mandé), Centre Hospitalier Universitaire Angers (Angers ), Centre Hospitalier Intercommunal Créteil (Créteil Cedex), Centre Hospitalier Universitaire de Grenoble (La Tronche) (and 7 more...)
Debiopharm International SA
Phase 3 Lung cancer
#NCT05607550
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic EGFR Systemic Treatment-Naive
Immunotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Centre François Baclesse (Caen ), Centre Léon Bérard (Lyon), Hôpital de la Croix Rousse - Hospices Civils de Lyon (Lyon), Hôpital Nord de Marseille (Marseille Cedex 20), Gustave Roussy (Villejuif) (and 1 more...)
ArriVent BioPharma, Inc
Phase 3 Lung cancer
#NCT05555732
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic Systemic Treatment-Naive PDL1 Negative (< 1%) PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%)
EGFR BRAF MET ALK RET ROS-1 NTRK-1/2/3 Other mutation Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Nantes (Nantes), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier), CHU de Rennes - Hôpital Pontchaillou (Rennes), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre Léon Bérard (Lyon) (and 6 more...)
Daiichi Sankyo
Phase 3 Lung cancer
#NCT04790253
SCLC (Small Cell Lung Cancer) Chemotherapy Chemotherapy
Centre Henri Becquerel (Rouen ), Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite) (and 7 more...)
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3 Lung cancer
#NCT06151574
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic HER2 Systemic Treatment-Naive
CHU de Rennes - Hôpital Pontchaillou (Rennes), Hôpital Tenon AP-HP (Paris ), Institut Curie - Paris (Paris), Gustave Roussy (Villejuif), Centre Léon Bérard (Lyon) (and 1 more...)
Boehringer Ingelheim
Phase 3 Lung cancer
#NCT05215340
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic Systemic Treatment-Naive PDL1 Positive (>= 50%)
EGFR BRAF MET ALK RET ROS-1 NTRK-1/2/3 Immunotherapy Targeted therapy Antibody Drug Conjugates (ADC) Immunotherapy Chemotherapy Targeted therapy Antibody Drug Conjugates (ADC)
Institut Bergonié (Bordeaux), Centre Hospitalier Universitaire de Lille (Lille), Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier), Hôpital Tenon AP-HP (Paris ), Hôpital Foch (Suresnes) (and 7 more...)
Daiichi Sankyo
Phase 3 Lung cancer
#NCT05211895
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Chemotherapy Radiotherapy PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
EGFR ALK
Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Centre Hospitalier François Mitterrand de Pau (Pau), Centre Hospitalier de Cornouaille (Quimper), Institut de Cancérologie Radiothérapie Brétillien / CHP Saint Grégoire - Vivalto Santé (Saint-Grégoire), Centre Hospitalier de Saint Quentin (Saint-Quentin) (and 7 more...)
AstraZeneca
Phase 3 Lung cancer
#NCT04222972
NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Locally Advanced Metastatic RET Systemic Treatment-Naive
EGFR BRAF MET ALK ROS-1
Gustave Roussy (Villejuif)
Hoffmann-La Roche